The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia
This is a one-center, three-arm, randomized, single-blinded, controlled trial. When a
patient was diagnosed VAP during mechanic ventilation in ICU,a sealed envelop will be opened
which decide whether the patient is assigned to the normal dose ulinastatin group,the high
dose ulinastatin group or the compare group.
VAP diagnosis and treatment accord with the "Comprehensive evidence-based clinical practice
guidelines for ventilator-associated pneumonia:Diagnosis and treatment" which was published
in 2008 by Canadian critical care trials group.
The aim of the present study is to determine the efficacy of ulinastatin for the treatment
of ventilator-associated Pneumonia(VAP) and to investigate the effect to inflammatory
factors in bronchoalveolar lavage fluid .
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Levels of inflammatory factors in bronchoalveolar lavage fluid and blood serum.
The variety of tumor necrosis factor-α(TNF-α),interleukin-10(IL-10),interleukin-18(IL-18) and interferon-γ(INF-γ) in bronchoalveolar lavage fluid and blood serum are observed.
China: Food and Drug Administration